Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)13(14)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 13,14-double bond of DHA. It has been detected in rat brain and spinal cord and is a preferred substrate for soluble epoxide hydrolase with a Km value of 3.2 μM. (±)13(14)-EpDPA demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models. (±)13(14)-EpDPA and other epoxy metabolites of DHA are also reported to potently inhibit angiogenesis and tumor growth in in vitro assays.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 μg | 約 35 days | ¥ 22,500 |
50 μg | 約 35 days | ¥ 45,000 |
100 μg | 約 35 days | ¥ 83,500 |
500 μg | 約 35 days | ¥ 367,500 |
説明 | Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)13(14)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 13,14-double bond of DHA. It has been detected in rat brain and spinal cord and is a preferred substrate for soluble epoxide hydrolase with a Km value of 3.2 μM. (±)13(14)-EpDPA demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models. (±)13(14)-EpDPA and other epoxy metabolites of DHA are also reported to potently inhibit angiogenesis and tumor growth in in vitro assays. |
分子量 | 344.495 |
分子式 | C22H32O3 |
CAS No. | 895127-64-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20 mg/mL
Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/mL
DMF: 25 mg/mL
Ethanol: 50 mg/mL
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(±)13(14)-EpDPA 895127-64-7 13(14)-EpDPA (±)13(14)EpDPA (±)13(14) EpDPA Inhibitor inhibitor inhibit